Article Text

Download PDFPDF
Cannabinoids in multiple sclerosis: urgent need for long term trials
  1. J Killestein,
  2. B M J Uitdehaag
  1. Department of Neurology, VU Medical Centre, Amsterdam, the Netherlands
  1. Correspondence to:
 Dr J Killestein
 Department of Neurology, VU Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The CAMS study represents a substantial step forward, but not the final one

Cannabinoids have been suggested for the treatment of numerous conditions, including cancer, vascular, neurodegenerative, and inflammatory diseases.1 Probably because of the nature of these substances, there is considerable interest in these drugs from the general public, lay media, and politicians. Frequently, the translation of scientific results is overly optimistic and may have contributed to extensive off label usage of cannabis among chronically ill patients. The evidence for therapeutic efficacy in humans is not as yet convincing.

The CAMS study2 by Zajicek and colleagues was the first large symptomatic trial of cannabinoids in multiple sclerosis (MS). In this study, 630 patients with stable MS and muscle spasticity were treated with delta-9-tetrahydrocannabinol (THC), cannabis extract or placebo. The main part of the …

View Full Text


  • Competing interests: Both authors participated in a clinical trial of cannabinoids in MS (

    ), which was financially supported by the Dutch Ministry of Health, Welfare and Sport.

Linked Articles